Edwards Lifesciences Corp (EW)
Solvency ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.06 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.10 | 0.09 | 0.10 | 0.11 | 0.11 |
| Debt-to-capital ratio | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 | 0.15 | 0.15 |
| Debt-to-equity ratio | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.15 | 0.15 | 0.14 | 0.16 | 0.17 | 0.17 |
| Financial leverage ratio | 1.41 | 1.41 | 1.41 | 1.45 | 1.43 | 1.39 | 1.42 | 1.44 | 1.46 | 1.47 | 1.49 | 1.55 | 1.58 | 1.62 | 1.67 | 1.56 | 1.56 | 1.56 | 1.59 | 1.59 |
The solvency ratios of Edwards Lifesciences Corp show a consistent and stable financial position over the past eight quarters. The debt-to-assets ratio has remained relatively low, around 0.06 to 0.07, indicating that only a small percentage of the company's total assets is financed by debt. This suggests a strong ability to cover obligations using its assets.
Similarly, the debt-to-capital and debt-to-equity ratios have also been steady between 0.08 to 0.10, demonstrating a conservative approach to financing through debt and equity. These ratios indicate a balanced capital structure with a reasonable level of leverage.
The financial leverage ratio has fluctuated slightly but remained within a narrow range of 1.39 to 1.45 over the quarters. This ratio reflects the proportion of the company's assets financed by debt compared to equity. The values suggest that Edwards Lifesciences Corp has maintained a stable level of financial leverage without excessive reliance on debt.
Overall, based on the solvency ratios, Edwards Lifesciences Corp appears to have a sound financial footing with a modest level of debt and a healthy mix of debt and equity in its capital structure. This stability indicates a prudent approach to managing financial risk and suggests a strong ability to meet its financial obligations in the long term.
Coverage ratios
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | 232.62 | 114.29 | 308.75 | 107.27 | 188.21 | 593.93 | 601.93 | 650.12 | 93.15 | 91.33 | 49.36 | 39.20 | 24.49 | 21.45 | 32.73 | 32.67 | 92.30 | 117.21 | 179.05 |
Based on the provided data, Edwards Lifesciences Corp did not report specific interest coverage ratios for Q4 2023, Q3 2023, Q2 2023, and Q1 2023. However, in Q1 2022, the interest coverage ratio was exceptionally high at 2,357.43. This indicates that in Q1 2022, the company's operating income was significantly higher compared to its interest expenses, reflecting a strong ability to meet its interest payment obligations. The lack of data for the subsequent quarters limits the ability to assess the trend or identify any changes in the company's interest coverage position. It would be important to monitor future financial reports to track the company's interest coverage performance over time.